Skip to main content

Aurolate Disease Interactions

There are 8 disease interactions with Aurolate (gold sodium thiomalate).

Major

Auranofin (applies to Aurolate) bone marrow aplasia

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

The use of auranofin and other gold compounds is contraindicated in patients with a history of gold- induced bone marrow aplasia. Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed. A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy. Hematological warning signs of gold toxicity include a drop in hemoglobin, leukopenia (WBC < 4,000/mm3), granulocytopenia (< 1,500/mm3), and thrombocytopenia (<100,000/mm3).

References

  1. "Product Information. Ridaura (auranofin)." SmithKline Beecham PROD (2001):
  2. "Product Information. Solganal (aurothioglucose)." Schering Corporation PROD (2001):
  3. "Product Information. Myochrysine (gold sodium thiomalate)." Merck & Co., Inc (2022):
Major

Gold compounds (applies to Aurolate) congestive heart failure

Major Potential Hazard, Moderate plausibility.

The use of gold compounds is contraindicated in patients with uncontrolled congestive heart failure. Prior to initiation of gold compounds medical problems that might affect the signs and symptoms used to detect gold compounds toxicity should be under control.

References

  1. "Product Information. Ridaura (auranofin)." SmithKline Beecham PROD (2001):
  2. "Product Information. Solganal (aurothioglucose)." Schering Corporation PROD (2001):
  3. "Product Information. Myochrysine (gold sodium thiomalate)." Merck & Co., Inc (2022):
Major

Gold compounds (applies to Aurolate) diabetes mellitus

Major Potential Hazard, Low plausibility.

The use of gold compounds is contraindicated in patients with controlled diabetes mellitus.

References

  1. "Product Information. Ridaura (auranofin)." SmithKline Beecham PROD (2001):
  2. "Product Information. Solganal (aurothioglucose)." Schering Corporation PROD (2001):
  3. "Product Information. Myochrysine (gold sodium thiomalate)." Merck & Co., Inc (2022):
Major

Gold compounds (applies to Aurolate) liver disease

Major Potential Hazard, High plausibility.

The use of gold compounds is contraindicated in patients with hepatic dysfunction. Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed. A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy.

References

  1. "Product Information. Ridaura (auranofin)." SmithKline Beecham PROD (2001):
  2. "Product Information. Solganal (aurothioglucose)." Schering Corporation PROD (2001):
  3. "Product Information. Myochrysine (gold sodium thiomalate)." Merck & Co., Inc (2022):
Major

Gold compounds (applies to Aurolate) rash

Major Potential Hazard, High plausibility. Applicable conditions: Eczema

The use of gold compounds is contraindicated in patients with urticaria or eczema. Prior to initiation of gold therapy, medical problems that might affect the signs and symptoms used to detect gold toxicity should be under control.

References

  1. "Product Information. Ridaura (auranofin)." SmithKline Beecham PROD (2001):
  2. "Product Information. Solganal (aurothioglucose)." Schering Corporation PROD (2001):
  3. "Product Information. Myochrysine (gold sodium thiomalate)." Merck & Co., Inc (2022):
Major

Gold compounds (applies to Aurolate) renal dysfunction

Major Potential Hazard, High plausibility.

The use of gold compounds is contraindicated in patients with chronic renal failure. These patients may be at increased risk for renal toxicity. Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed. A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy.

References

  1. "Product Information. Ridaura (auranofin)." SmithKline Beecham PROD (2001):
  2. "Product Information. Solganal (aurothioglucose)." Schering Corporation PROD (2001):
  3. "Product Information. Myochrysine (gold sodium thiomalate)." Merck & Co., Inc (2022):
Major

Gold compounds (applies to Aurolate) severe hypertension

Major Potential Hazard, Moderate plausibility.

The use of gold compounds is contraindicated in patients with severe hypertension. Prior to initiation of gold compounds medical problems that might affect the signs and symptoms used to detect gold compounds toxicity should be under control.

References

  1. "Product Information. Ridaura (auranofin)." SmithKline Beecham PROD (2001):
  2. "Product Information. Solganal (aurothioglucose)." Schering Corporation PROD (2001):
  3. "Product Information. Myochrysine (gold sodium thiomalate)." Merck & Co., Inc (2022):
Major

Gold compounds (applies to Aurolate) systemic lupus erythematosus

Major Potential Hazard, High plausibility.

The use of gold compounds is contraindicated in patients with systemic lupus erythematosus. Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed. A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy.

References

  1. "Product Information. Ridaura (auranofin)." SmithKline Beecham PROD (2001):
  2. "Product Information. Solganal (aurothioglucose)." Schering Corporation PROD (2001):
  3. "Product Information. Myochrysine (gold sodium thiomalate)." Merck & Co., Inc (2022):

Aurolate drug interactions

There are 129 drug interactions with Aurolate (gold sodium thiomalate).

Aurolate alcohol/food interactions

There is 1 alcohol/food interaction with Aurolate (gold sodium thiomalate).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer